Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy
13
lượt xem 0
download
lượt xem 0
download
Download
Vui lòng tải xuống để xem tài liệu đầy đủ
Preclinical studies have documented antitumor activity of PARP inhibition both in vitro and in vivo, against Ewing sarcoma cells. This study aimed to translate that observation into a clinical trial to assess the efficacy and tolerability of olaparib, a PARP inhibitor, in patients with advanced Ewing sarcoma (EWS) progressing after prior chemotherapy.
Chủ đề:
Bình luận(0) Đăng nhập để gửi bình luận!
CÓ THỂ BẠN MUỐN DOWNLOAD